Nanjing Sanhome Pharmaceutical Co., Ltd, a notable player in the pharmaceutical sector, has announced the widespread distribution of its Category 1 chemical drug, oritinib, across key regions in China, including Jiangsu, Shanghai, Beijing, Henan, and Inner Mongolia. The drug has been made available to lung cancer specialists who are now prescribing it to patients.
Oritinib, an epidermal growth factor receptor (EGFR) inhibitor, received marketing approval in China in June 2024. It is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has an EGFR T790M mutation. The drug is prescribed to patients who have experienced disease progression during or after prior treatment with EGFR tyrosine kinase inhibitors (TKIs).- Flcube.com
